Test Price
450 AED✅ Home Collection Available
CD8 Immunohistochemistry IHC Test – Oncology Immunoprofiling | 450 AED | Dubai Healthcare City
Executive Summary & Core Metrics
- ✓ Clinical Accuracy: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited immunohistochemistry processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Specimen Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for FFPE blocks and biopsy samples – ISO-certified cold-chain transport available daily from 8 AM to 11 PM.
- ✓ Post-Test Guidance: Complimentary telephonic clinical result interpretation by DHA-licensed oncology specialists.
- ✓ Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CD8 Immunohistochemistry (IHC) Test is a specialised tissue-based assay that detects and quantifies CD8-positive cytotoxic T lymphocytes within the tumour microenvironment. This immuno-oncological profiling tool provides critical data for cancer prognosis, immunotherapy response prediction, and treatment stratification in solid malignancies.
| Parameter | DNA Labs UAE CD8 IHC (Premium) | Alternative Approach (Flow Cytometry) |
|---|---|---|
| Diagnostic Precision | Spatial tissue-contextual analysis with morphological correlation; 99.9% sensitivity | Suspension-based cell counting; tissue architecture lost |
| Methodology | IHC on FFPE with DAB chromogen detection and digital pathology scoring | Flow cytometry with fluorescent-labelled anti-CD8 antibodies |
| Turnaround Time | 5–7 days (tissue-dependent) | 3–5 days (requires fresh tissue or blood) |
| Clinical Applicability | Gold standard for tumour microenvironment assessment and immunotherapy guidance | Limited to circulating or peripheral CD8 quantification |
| Price (AED) | 450 AED | 350–500 AED (variable) |
Physician Insight & Safety Protocols
Clinical Note from Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA License: 61713011):
"The CD8 IHC provides a powerful window into your immune system's engagement with the tumour. Every result must be interpreted within the full context of your histopathology report and clinical history — no single biomarker tells the complete story. Our clinical team is available after your report is issued to guide you through every finding with clarity and compassion."
Medication Advisory
⚠ Do not discontinue any prescribed medication — including corticosteroids, immunosuppressants, or chemotherapy agents — without consulting your treating physician. CD8 IHC results are adjunctive and should never independently dictate treatment modifications.
Patient Exclusion Criteria & Emergency Red Flags
Pre-Test Exclusion Criteria
- Inadequate or necrotic tumour tissue specimen (non-viable for IHC staining)
- Unfixed or improperly preserved biopsy material (must be 10% formal-saline or FFPE block)
- Missing histopathology report — mandatory for valid interpretation
- Known hypersensitivity to IHC detection reagents (rare; disclose prior reactions)
Emergency Red Flags – Seek Immediate Care If
- Biopsy site develops uncontrolled bleeding, purulent discharge, or expanding hematoma
- Fever exceeding 38.5°C within 48 hours post-biopsy
- Sudden onset of severe pain, dyspnea, or tachycardia unrelated to known conditions
- Any signs of anaphylaxis: urticaria, angioedema, or throat tightness
Per Federal Decree-Law No. 4 of 2016 on Medical Liability, all minor patients require documented guardian consent. Patient data privacy is governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Patient FAQ & Clinical Guidance
1. What does the CD8 IHC test measure and why is it important for cancer patients?
The CD8 IHC test measures the density and distribution of CD8-positive cytotoxic T lymphocytes within your tumour tissue – the immune cells that directly attack cancer cells. Their presence is a powerful predictor of immunotherapy response and overall survival. The test uses monoclonal antibodies targeting the CD8 protein on T-cell surfaces, enabling pathologists to visualise and count these immune defenders under microscopy. High CD8+ T-cell infiltration often correlates with better prognosis and enhanced responsiveness to immune checkpoint inhibitors. Your oncologist uses this data to stratify risk, personalise treatment, and determine whether immunotherapy is likely to benefit you.
2. How should I prepare for the CD8 IHC test and how is the specimen collected?
No personal preparation is required. The test is performed on a tumour biopsy specimen already collected by your surgeon or interventional radiologist. The tissue must be submitted as a formalin-fixed paraffin-embedded (FFPE) block or in 10% formal-saline solution. Our Secure Medical Courier Solid Tissue Specimen Retrieval service can collect your FFPE block or tissue sample from your location using ISO-certified cold-chain transport, ensuring complete specimen integrity from pickup to laboratory processing. You must provide a copy of your histopathology report, biopsy site documentation, and complete clinical history at submission – without these, accurate IHC interpretation cannot be guaranteed.
3. How accurate is CD8 IHC testing and how are results used in treatment planning?
Our CD8 IHC test delivers 99.9% diagnostic sensitivity through ISO 9001:2015 accredited processing and digital pathology validation. Results are reported as the percentage of CD8+ cells per high-power field along with distribution pattern analysis – intratumoral, peritumoral, or stromal. High CD8 infiltration typically supports immunotherapy candidacy, while low levels may prompt alternative strategies. All reports include complimentary telephonic clinical guidance from our DHA-licensed specialists to ensure you and your physician fully understand the implications before any treatment change is made.
UAE Regulatory & Data Privacy Adherence
- ● DHA Facility License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
- ● ISO 9001:2015 Certified – Cert: INT/EGQ/2509DA/3139
- ● Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – Full Compliance
- ● Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – Full Compliance
- ● Federal Decree-Law No. 4 of 2016 on Medical Liability – Patient Consent Protocols Observed
Clinical & Logistical Metadata
| Test Name | CD8 Immunohistochemistry (IHC) Test |
| Price (AED) | 450 AED |
| Turnaround Time | 5–7 days (FFPE block: 5 days; large complex tissue: 7 days) |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) tissue block or tumour biopsy in 10% formal-saline |
| Methodology Used | Immunohistochemistry (IHC) using monoclonal anti-CD8 antibodies with DAB chromogen detection and digital pathology scoring on FFPE sections |
| ICD-10-CM Code | C80.1, Z51.11, D48.7 |
| LOINC Code | 11579-0 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians